** Shares of biopharma firm Edgewise Therapeutics EWTX fall 39.4% to $12.20
** EWTX says its experimental drug, EDG-7500, when tested in patients with Hypertrophic cardiomyopathy $(HCM)$, was able to meaningfully reduce LVOT gradients, a predictor of heart failure
** But patients who took the drug reported dizziness and respiratory tract infections, with one patient discontinuing the trial due to dizziness
** Brokerage RBC Capital Market says "while there may be some questions around safety, we think the profile is manageable"
** RBC says the efficacy markers from this trial are "relatively modest" compared with early-stage study data
** Shares of rival Cytokinetics CYTK.O, which is developing experimental heart drug aficamten, rise 12% to $42
** HCM is characterized by thickening of the heart muscle, affecting its ability to pump blood
** As of last close, EWTX has risen 11.7% in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.